Aripiprazole offsets mutant atxn3-induced motor dysfunction by targeting dopamine d2 and serotonin 1a and 2a receptors in c. elegans

HIGHLIGHTS

• who: Ana Jalles and colleagues from the Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, have published the paper: Aripiprazole Offsets Mutant ATXN3-Induced Motor Dysfunction by Targeting Dopamine D2 and Serotonin 1A and 2A Receptors in C. elegans, in the Journal: Biomedicines 2022, 10, 370. of /2022/
• what: The authors focus on confirming the efficacy of aripiprazole to reduce motor dysfunction in vivo using a Caenorhabditis elegans (C. elegans) model of MJD and on unveiling the drug targets required for its positive action against mutant ATXN3 pathogenesis. The authors . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.